Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
99
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

Chen Shi1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Xiong Wang1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Changdong Diao1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Haixia Zhu1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Qi Yuan1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Jinmei Liu1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Shijun Li1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
,
Ming Gu1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Yu Zhang1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People’s Republic of China;2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People’s Republic of ChinaView further author information
 show all
Pages 2151-2159 | Published online: 20 May 2021

References

  • FriedmanHS, KerbyT, CalvertH. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585–2597.10914698
  • GriecoA, TafuriMA, BiolatoM, et al. Severe cholestatic hepatitis due to temozolomide: anadverse drug effect to keep in mind. Case report and review of literature. Medicine(Baltimore). 2015;94(12):e476. doi:10.1097/MD.000000000000047625816026
  • HeJ, ChH. Research progress on resistance mechanism of temozolomide in treatment of glioblastoma(in Chinese). Chin J Mod Appl Pharm. 2019;36(23):3001–3007. doi:10.13748/j.cnki.issn1007-7693.2019.23.024
  • NiuXD, MaDW, TianHL, et al. Efficacy of temozolomide versus traditional Chemotherap- -eutic drugs in the treatment of glioma: a systematic review(in Chinese). J Int Neuro Neurosurg. 2014;41(1):1–6.
  • BaiY, ChenY, HongX, et al. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. Sci Rep. 2018;8(1):11470. doi:10.1038/s41598-018-29929-y30065314
  • RogerS, MonikaEH, WarrenPM, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/S1470-2045(09)70025-719269895
  • Sastre-GallegoS, Fernández-LizarbeE, Martín-SánchezM, et al. EP-1204: limited margin radiotherapy and temozolomide for glioblastoma multiforme: pattern of failure. Radiother Oncol. 2018;127:S671. doi:10.1016/S0167-8140(18)31514-7
  • SilkeBN, GabiS, HendrikB, et al. Temozolomide during radiotherapy of glioblastoma Multiforme:Dailyadministration improves survival. Strahlenther Onkol. 2017;193(11):890–896. doi:10.1007/s00066-017-1110-428197654
  • WeeCW, KimE, KimTM, et al. Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. J Neurooncol. 2017;134(1):169–175. doi:10.1007/s11060-017-2505-x28547592
  • BrachmanDG, WangM, AshbyLS, et al. Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): results of RTOG 0513. Int J Radiat Oncol Bio Phys. 2011;81(2):S129–S130. doi:10.1016/j.ijrobp.2011.06.267
  • BradaM, StenningS, GabeR, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601–4608. doi:10.1200/JCO.2009.27.193220855843
  • CTCAE v4.0, Common terminology criteria for adverse events [EB/OL]; 2011. Available from: http://www.calgb.org/Public/meetings/presentations/2009/summer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf. Accessed 58, 2021.
  • BradaM, Hoang-XuanK, RamplingR, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12(2):259–266. doi:10.1023/a:100838251663611300335
  • ChuaSL, RosenthalMA, WongSS, et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 2004;6(1):38–43. doi:10.1215/S115285170300018814769139
  • BrandesAA, ErmaniM, BassoU, et al. Temozolomide in patients with glioblastoma at second relapse after fifirst line nitrosourea-procarbazine failure: a phase II study. Oncol. 2002;63(1):38–41. doi:10.1159/000065718
  • ZhouB, MaoQ, WangP, et al. The Adverse Effects Analysis of Temozolomide in Glioma Chemotherapy(in Chinese). Chin J Neurooncol. 2012;10(1):14–18.
  • ArmstrongTS, CaoY, ScheurerME, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009;11(6):825–832. doi:10.1215/15228517-2008-12019179423

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.